Literature DB >> 33539195

Cell-based influenza vaccine: current production, halal status assessment, and recommendations towards Islamic-compliant manufacturing.

Nurul Nadiah Zulkarnain1, Nurina Anuar1, Norliza Abd Rahman1, Siti Rozaimah Sheikh Abdullah1, Muhammad Nazir Alias2, Mashitoh Yaacob3,4, Zhongren Ma5, Gongtao Ding5.   

Abstract

Influenza virus is a life-threatening pathogen that infects millions of people every year, with annual mortality in the hundreds of thousands. The scenario for controlling infection has worsened with increasing numbers of vaccine hesitancy cases reported worldwide due to objections on safety, religious and other grounds. Uses of haram (impermissible) and mashbooh (doubtful) ingredients in vaccine production has raised doubts among Muslim consumers and consequently stimulated serious vaccine hesitancy. To address this major problem, we have reviewed and recommended some alternatives appropriate for manufacturing cell-based influenza vaccine which comply with Islamic laws and consumers' needs. Intensive assessments of current influenza vaccine production in both scientific and Islamic views have led to the identification of four main ingredients deemed impermissible in novel sharia-compliant (approved by Islamic laws) vaccine manufacturing. Only some of these impermissible components could be replaced with halal (permissible) alternatives, while others remain impermissible due to unavailability and unsuitability.

Entities:  

Keywords:  Cell-based influenza vaccine; Islamic law; halal pharmaceutical; impermissible ingredient; sharia-compliant vaccine manufacturing; vaccine hesitancy

Mesh:

Substances:

Year:  2021        PMID: 33539195      PMCID: PMC8189117          DOI: 10.1080/21645515.2020.1865044

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  58 in total

1.  Alternatives to the use of fetal bovine serum: serum-free cell culture.

Authors:  Gerhard Gstraunthaler
Journal:  ALTEX       Date:  2003       Impact factor: 6.043

2.  Amino acid metabolism in mammalian cell cultures.

Authors:  H EAGLE
Journal:  Science       Date:  1959-08-21       Impact factor: 47.728

Review 3.  Vaccine process technology.

Authors:  Jessica O Josefsberg; Barry Buckland
Journal:  Biotechnol Bioeng       Date:  2012-03-30       Impact factor: 4.530

4.  Biological activity of residual cell-substrate DNA.

Authors:  K Peden; L Sheng; A Pal; A Lewis
Journal:  Dev Biol (Basel)       Date:  2006

5.  A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.

Authors:  Samia Rourou; Arno van der Ark; Tiny van der Velden; Héla Kallel
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

6.  Influenza A virus isolation, culture and identification.

Authors:  Amie J Eisfeld; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Nat Protoc       Date:  2014-10-16       Impact factor: 13.491

Review 7.  Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.

Authors:  Ozan S Kumru; Sangeeta B Joshi; Dawn E Smith; C Russell Middaugh; Ted Prusik; David B Volkin
Journal:  Biologicals       Date:  2014-07-01       Impact factor: 1.856

8.  New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.

Authors:  V Lohr; A Rath; Y Genzel; I Jordan; V Sandig; U Reichl
Journal:  Vaccine       Date:  2009-06-14       Impact factor: 3.641

9.  Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Authors:  Alan Yung-Chih Hu; Yu-Fen Tseng; Tsai-Chuan Weng; Chien-Chun Liao; Johnson Wu; Ai-Hsiang Chou; Hsin-Ju Chao; Anna Gu; Janice Chen; Su-Chen Lin; Chia-Hsin Hsiao; Suh-Chin Wu; Pele Chong
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

Review 10.  Downstream processing of cell culture-derived virus particles.

Authors:  Michael W Wolf; Udo Reichl
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

View more
  1 in total

1.  COVID-19 vaccine hesitancy in Malaysia: Exploring factors and identifying highly vulnerable groups.

Authors:  Adi Jafar; Ramzah Dambul; Ramli Dollah; Nordin Sakke; Mohammad Tahir Mapa; Eko Prayitno Joko
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.